BioMarin Pharmaceutical Inc. (BMRN)

BioMarin's stock has been impacted by the acquisition of Amicus Therapeutics, expected to accelerate revenue growth but be slightly dilutive to full-year 2026 Non-GAAP Diluted EPS. The company raised its full-year 2026 revenue guidance. In February 2026, BioMarin reported its fourth-quarter and full-year 2025 results, including a GAAP Net Loss due to the withdrawal of Roctavian. The company's stock performance has seen a decline over the past 12 months. On May 4, 2026, BioMarin reported first-quarter 2026 financial results, with Q1 profit dropping as the Amicus acquisition ramps up, but sales beat estimates.

Demand for BioMarin Pharmaceutical's products and services does not follow traditional seasonal patterns but is driven by ongoing patient needs for rare genetic conditions and global expansion efforts. Strong global demand for Voxzogo and increased patient demand for Enzyme Therapies across all regions have been reported.

BioMarin Pharmaceutical, Inc. is an American biotechnology company specializing in therapies for rare genetic diseases, focusing on enzyme replacement therapies, gene therapies, and other advanced approaches. Its commercial product portfolio includes medicines for rare genetic disorders such as Vimizim, Naglazyme, Palynziq, Brineura, Aldurazyme, Kuvan, and Voxzogo. BioMarin acquired Amicus Therapeutics in April 2026, adding Galafold and Pombiliti + Opfolda to its portfolio.

BioMarin Pharmaceutical Inc. is headquartered in San Rafael, California, and has a significant international presence with offices and facilities across the United States, South America, Asia, and Europe. The company's commercial reach extends to over 80 countries. Manufacturing operations are conducted at facilities in Novato, California, and Shanbally, Ireland.

BioMarin Pharmaceutical's brand reputation has seen a positive shift, with the company being one of only three U.S. companies whose reputation significantly improved among patient groups, according to an April 2026 PatientView survey.

Institutional investors are the primary owners of BioMarin Pharmaceutical, Inc., holding over 95% of the company's shares. Major institutional shareholders include BlackRock, Inc., The Vanguard Group, Inc., PRIMECAP Management Company, Dodge & Cox, and Viking Global Investors LP.